Autograft immune effector cells and survival in autologous peripheral blood hematopoietic stem cell transplantation

Porrata, Luis F.

doi:10.1002/jca.21611

Cited by 13 publications

(14 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CD34 + CD133 + CD38 − cell content in the grafts have also been shown to affect hematologic recovery 15 . The graft natural killer (NK) cell content has been linked to early lymphocyte recovery (absolute lymphocyte count at Day 15), which has been suggested to be associated with better prognosis 16–18 …”

Section: Introductionmentioning

confidence: 99%

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

et al. 2020

View full text Add to dashboard Cite

Background Diffuse large B‐cell lymphoma (DLBCL) is a common indication for autologous stem cell transplantation (auto‐SCT). Study Design and Methods This prospective noninterventional study aimed to evaluate the impact of mobilization characteristics and graft cellular content on hematologic recovery and outcome after auto‐SCT among 68 patients with DLBCL. Results Better mobilization capacity as manifested by blood CD34+ cell count >32 × 106/L and CD34+ cell yield of the first apheresis >2.75 × 106/kg correlated with faster neutrophil (P = .005 and P = .017) and platelet (P = .002 and P < .001) recovery. A higher number of infused CD34+ cells (> 2.65 × 106/kg) was associated with better 5‐year overall survival (OS; 95% vs 67%, P = .012). The graft CD34+CD133+CD38− cell count >0.07 × 106/kg was predictive of better 5‐year OS (87% vs 63%; P = .008) and higher graft CD3+ cell count (>23.1 × 106/kg) correlated also with better 5‐year OS (80% vs 40%, P = .008). In multivariate analysis only disease status of CR I at auto‐SCT was associated with better progression‐free survival (P = .014) and OS (P = .039). Conclusion The mobilization capacity of CD34+ cells impacted on early hematologic recovery in patients with DLBCL after auto‐SCT. Higher graft CD34+ cell count and both CD34+CD133+CD38− and CD3+ cells were also associated with better OS. The effect of optimal graft cellular composition on outcome in DLBCL should be evaluated in a randomized study.

show abstract

Section: Introductionmentioning

confidence: 99%

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…T-cells also show functional abnormalities for 6 months to several years. Finally, NK cell levels and functions normalise within a few weeks.Patients with early lymphoid reconstitution seem to have a more favourable prognosis than patients with late reconstitution (generally evaluated on day +15 or +30 posttransplant)[472][473][474][475]. This prognostic impact of early lymphoid reconstitution suggests that early posttransplant events are important for outcomes after autologous stem cell transplantation.…”

mentioning

confidence: 99%

Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood

Rundgren

Bruserud

Ryningen

et al. 2018

Journal of Immunological Methods

View full text Add to dashboard Cite

show abstract

“…With plerixafor-induced mobilization more immature CD34+/CD38-cells and T- and NK-cells are collected, which can lead to faster hematopoietic recovery after transplantation. 46 , 47 Few studies have shown that the grafts of MM patients had a higher number of NK-cells and CD19+ cells than those of NHL patients. However, no difference was observed in recovery.…”

Section: Use Of Plerixafor For Autologous Sctmentioning

confidence: 99%

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update

Bilgin¹

2021

JBM

View full text Add to dashboard Cite

Mobilization failure is an important issue in stem cell transplantations. Stem cells are yielded from the peripheral blood via apheresis. Granulocyte colony-stimulating factor (G-CSF) is the most commonly used mobilization agent among patients and donors. G-CSF is administered subcutaneously for multiple days. However, patients with mobilization failure cannot receive autologous stem cell transplantation and, therefore, cannot be treated adequately. The incidence rate of mobilization failure among patients is about 6–23%. Plerixafor is a molecule that inhibits the binding of chemokine receptor-4 with stromal-cell-derived factor-1, thereby resulting in the release of CD34+ cells in the peripheral blood. Currently, plerixafor is used in patients with mobilization failure with G-CSF and is administered subcutaneously. Several studies conducted on different clinical settings have shown that plerixafor is effective and well tolerated by patients. However, more studies should be conducted to explore the optimal approach for plerixafor in patients with mobilization failure. The incidence of mobilization failure among donors is lower. However, plerixafor is not approved among donors with mobilization failure. Moreover, several clinical studies in donors have shown a beneficial effect of plerixafor. In addition, the adverse events of plerixafor are mild and transient, which can overcome the adverse events due to G-CSF. This review assessed the current role and effects of plerixafor in stem cell mobilization for autologous and allogeneic stem cell transplantations.

show abstract

Autograft immune effector cells and survival in autologous peripheral blood hematopoietic stem cell transplantation

Cited by 13 publications

References 39 publications

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update

Contact Info

Product

Resources

About